Iqvia Holdings Inc (NYSE:IQV) Director John Connaughton Sells 1,163,191 Shares

Iqvia Holdings Inc (NYSE:IQV) Director John Connaughton sold 1,163,191 shares of Iqvia stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $118,645,482.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

John Connaughton also recently made the following trade(s):

  • On Tuesday, September 19th, John Connaughton sold 1,030,429 shares of Iqvia stock. The shares were sold at an average price of $94.87, for a total value of $97,756,799.23.

Shares of Iqvia Holdings Inc (IQV) traded down $0.41 during midday trading on Friday, hitting $97.90. The company had a trading volume of 839,812 shares, compared to its average volume of 1,141,990. The firm has a market cap of $20,447.29, a PE ratio of 337.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.61. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia Holdings Inc has a twelve month low of $74.80 and a twelve month high of $110.67.

Iqvia (NYSE:IQV) last issued its earnings results on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.05. The business had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. Iqvia’s revenue was up 77.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.00 earnings per share. sell-side analysts expect that Iqvia Holdings Inc will post 4.62 EPS for the current year.

Several equities analysts have recently issued reports on the company. Royal Bank of Canada assumed coverage on Iqvia in a research report on Tuesday, September 19th. They set an “outperform” rating and a $116.00 price target on the stock. KeyCorp reiterated a “buy” rating and set a $100.00 price target on shares of Iqvia in a research report on Sunday, September 24th. Zacks Investment Research upgraded Iqvia from a “hold” rating to a “buy” rating and set a $114.00 price target on the stock in a research report on Saturday, October 21st. Barclays lifted their price target on Iqvia from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. Finally, Stifel Nicolaus upgraded Iqvia from a “hold” rating to a “buy” rating and lifted their price target for the company from $92.00 to $128.00 in a research report on Friday, October 27th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and a consensus target price of $106.94.

TRADEMARK VIOLATION NOTICE: “Iqvia Holdings Inc (NYSE:IQV) Director John Connaughton Sells 1,163,191 Shares” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://weekherald.com/2017/12/30/insider-selling-iqvia-holdings-inc-iqv-director-sells-118645482-00-in-stock.html.

About Iqvia

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply